

Addiphos®

CAUTION: High Administration Risk Rating	
Form	Addiphos [®] concentrate containing potassium dihydrogen phosphate, disodium phosphate dihydrate and potassium hydroxide One vial (20 mL Addiphos) provides the following: Phosphate 40 mmol, Potassium 30 mmol, Sodium 30 mmol
Reconstitution	In solution. Must be diluted before administration
Compatibility & Stability	Glucose 5% Sodium chloride 0.9% Addiphos [®] must not be added to infusions containing Addamel [/] Additrace due to the risk of precipitation.
Administration	 IV infusion: Dilute and give slowly over at least 6 hours using an infusion pump. The rate of administration should be appropriate to correct electrolyte deficiency and suitable for individual fluid requirements. Administration via a central venous access device is preferred. If diluted sufficiently, Addiphos® may be given via a large peripheral vein. IV infusion via a peripheral line: Add 10mL Addiphos® to 500mL glucose 5%. Mix well This provides approximately: 20mmol phosphate (0.04mmol in 1mL) 15mmol potassium (0.03mmol in 1mL) 15mmol sodium (0.03mmol in 1mL) 15mmol sodium (0.03mmol in 1mL) 15mmol potassium (0.03mmol in 1mL) 30mmol phosphate (0.053mmol in 1mL) 30mmol potassium (0.04mmol in 1mL) 30mmol sodium (0.04mmol in 1mL) 30mmol sodium (0.04mmol in 1mL) 15mmol sodium (0.04mmol in 1mL) 30mmol sodium (0.04mmol in 1mL) 30mmol potassium (0.04mmol in 1mL) 30mmol potassium (0.04mmol in 1mL) 30mmol potassium (0.04mmol in 1mL) 30mmol sodium (0.04mmol in 1mL) 30mmol sodium (0.04mmol in 1mL) 30mmol sodium (0.04mmol in 1mL) 30mmol potassium (0.04mmol in 1mL) 30mmol potassium (0.04mmol in 1mL) 30mmol sodium (0.04mmol in 1mL) 30mmol sodium (0.04mmol in 1mL) 30mmol sodium (0.04mmol in 1mL) 30mmol potassium (0.04mmol in 1mL) 30mmol potassium (0.04mmol in 1mL) 30mmol sodium (0.04mmol in 1mL)
Monitoring	15mmol sodium (0.3mmol in 1mL)Monitor serum electrolytes (calcium, phosphate, potassium, sodium), renal function, fluid balance, acid-base balance, ECG, blood pressure.
Extravasation	Extravasation is likely to cause tissue damage due to high osmolarity (more likely with higher concentrations). Monitor the peripheral insertion site closely and resite at first signs of inflammation.
Additional Information	 Addiphos[®] contains potassium. The maximum infusion rate for Addiphos[®] is 10mmol potassium per hour. Correction of phosphate with Addiphos[®] is unlicensed.

Information relates to Addiphos[®] manufactured by Fresenius Kabi.

This information has been summarised to act as a guide for those administering IV medication. The monograph should be used in conjunction with the drug data sheet and BNF for information on dose, adverse effects, cautions and contra-indications. Further information is available from Pharmacy on 22146 or 22542